| SEC Fo | rm 4 FORM | 4 | UNIT | ED ST/ | ATES | S SE | CURITI | ES A | | EXCHA | NGE | CON | IMIS | SION | | | | |
|-----------------------------------------------------------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|-----------------------------------------|-------------------------------|-------------------------------------------------------------------------------------------------|-----------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------------------------------------|---------------------------|-----------------------------------------------------------------------------------------------|--------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-------------------------------------------------------------------|---------------|-------------------------------------------------------------------|---------|
| | | | Washington, D.C. 20549 | | | | | | | | | OMB APPROVAL | | | | | | |
| Sectio obligat | this box if no lo n 16. Form 4 or tions may conti ction 1(b). | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | | | | | | | | | | ΙP | Estima | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | | | | |
| 1. Name and Address of Reporting Person* Crowley John F | | | | | | 2. Issuer Name and Ticker or Trading Symbol <u>AMICUS THERAPEUTICS, INC.</u> [FOLD] | | | | | | | | k all applic Directo | able) r | | Own | Dwner |
| (Last) (First) (Middle) C/O AMICUS THERAPEUTICS, INC. 1 CEDAR BROOK DRIVE | | | | | _ | 3. Date of Earliest Transaction (Month/Day/Year) 12/15/2020 | | | | | | | | X Officer (give title Other (spe- below) below) Chairman & CEO | | | | lecity |
| (Street) CRANBURY NJ 08512 | | | | | - 4. I | | | | | | | | 6. Indi Line) X | -) | | | | |
| (City) (State) (Zip) | | | | | | | | | | | | | <u> </u> | | | | | |
| Iable I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/Y) | | | | ion | 2A. Deemed Execution Date, | | 3. Transaction Code (Instr. 8) | | isposed of, or Benefic 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and | | | 5. Amount o | | es ally =ollowing | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | of Be O | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | | Code | v | Amount | (A) or (D) | Price | | Transac (Instr. 3 | tion(s) | | | (| |
| Common Stock 12/15/2 | | | | 020 | 20 | | М | | 22,000 | Α | \$6 | .45 | 845 | 5,513 | D | | | |
| Common Stock 12/15/20 | | | | | 020 | 20 | | S ⁽¹⁾ | | 22,000 | D | \$23.9 |)137 ⁽²⁾ | 823 | 3,513 | D | | |
| Common Stock | | | | | | | | | | | | | | 64 | ,895 | I | В | y Trust |
| | | - | Table I | | | | | | | sposed of, s, converti | | | | wned | | | | |
| 1. Title of Derivative Security (Instr. 3) | ve Conversion Date (Month/Day/Year) 3A. Deemed Execution Date if any | | ion Date, | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. | Expira (Mont | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) 9. Numbe derivative Security Beneficia Owned Following Reported Transacti (Instr. 4) | | e Owners Form: Ily Direct (I or Indire (I) (Instr |) ct | 11. Natur of Indired Beneficia Ownersh (Instr. 4) | |

or Number Date Exercisable Expiration Date of v Title Shares Code (A) (D) Stock Options Common \$<mark>6.4</mark>5 12/15/2020 М (3) 02/15/2022 22,000 22,000 \$0.00 (right to buy) Stock

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

2. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$23.55 to \$24.13 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. All of these options were fully vested and exercisable as of December 15, 2020.

Remarks:

In addition to the reported transactions, Mr. Crowley also has approximately 1.50 million options outstanding and exercisable at various strike prices.

<u>/s/ Christian Formica, Attorney-</u> 12/16/2020 in-Fact ** Signature of Reporting Person Date

Amount

108,557

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.